- Perifosine
-
- $39.00 / 2mg
-
2026-02-01
- CAS:157716-52-4
- Min. Order:
- Purity: 99.80%
- Supply Ability: 10g
- Perifosine
-
- $0.00 / 1g
-
2020-07-22
- CAS:157716-52-4
- Min. Order: 1g
- Purity: 99.0%
- Supply Ability: 500kg/month
- Perifosine (KRX-0401)
-
- $2.00 / 1kg
-
2019-07-06
- CAS:157716-52-4
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 100kg
|
| | Perifosine (KRX-0401) Chemical Properties |
| Melting point | 271-272° (dec) | | storage temp. | -20°C | | solubility | H2O: soluble10mg/mL, clear | | form | powder | | color | white to beige | | Water Solubility | H2O: 10mg/mL, clear | | InChI | InChI=1S/C25H52NO4P/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-24-29-31(27,28)30-25-20-22-26(2,3)23-21-25/h25H,4-24H2,1-3H3 | | InChIKey | SZFPYBIJACMNJV-UHFFFAOYSA-N | | SMILES | C1(OP([O-])(=O)OCCCCCCCCCCCCCCCCCC)CC[N+](C)(C)CC1 | | CAS DataBase Reference | 157716-52-4 |
| WGK Germany | 3 | | HS Code | 2933399990 | | Storage Class | 11 - Combustible Solids |
| | Perifosine (KRX-0401) Usage And Synthesis |
| Description | Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3. | | In vitro | Perifosine develops anti-proliferative properties with IC50 of 0.6-8.9 μM in immortalized keratinocytes (HaCaT), and head and neck squamous carcinoma cells. Perifosine strongly reduces phosphorylation levels of Akt and extracellular signal-regulated kinase (Erk) 1/2, induces cell cycle arrest in G1 and G2, and causes dose-dependent growth inhibition of mouse glial progenitors. Perifosine (10 μM) completely inhibits the phosphorylation of Akt in MM.1S cells. A recent study demonstrates Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation.
| | In vivo | Perifosine combining with temozolomide reduces tumor proliferation (a PDGF-driven gliomagenesis) in vivo. The results indicate that Perifosine is an effective drug in gliomas in which Akt and Ras-Erk 1/2 pathways are frequently activated, and may be new candidate for glima treatment in the clinic. Both oral daily and weekly administration of Perifosine significantly reduce human MM tumor growth and increase survival, compared with control animals treated with PBS vehicle only. Perifosine induces thrombocytosis and leukocytosis and increases myelopoiesis in murine marrow and spleen, whereas it causes apoptosis in myeloma xenografts.
| | Uses | Antineoplastic. | | Uses | It acts as an Akt inhibitor and a PI3K inhibitor, and is a drug candidate being developed for a variety of cancer indications. | | Uses | An alkylphospholipid which inhibits Akt activation and the anti-apoptotic MAPK pathway. | | Definition | ChEBI: A phospholipid consisting of 1,1-dimethylpiperidinium-4-yl hydrogen phosphate in which the hydrogen is replaced by a stearyl (octadecyl) group. | | Biological Activity | perifosine is an inhibitor of akt [1].perifosine is a synthetic antitumor alkylphospholipid. it induces cell apoptosis through inhibiting the activity of akt. perifosine shows antitumor activity in various cell lines including nsclc, mm, epithelial carcinoma, prostate carcinoma and leukemia cells. in h460 cells, perifosine decreased cell survival and induced apoptosis with ic50 values of 1μm and 10 μm, respectively. the treatment of perifosine was also found to induce cleavage of caspase-8, caspase-9, caspase-3 and parp in this cell line. in mm.1s cells, perifosine induced sub-g1 phase population increase from 15% to 57% at 10 μm and induced cleavage of caspase-8, caspase-9 and parp in a dose-dependent manner. in mice inoculated with mm.1s cells, oral administration of perifosine significantly reduced mm tumor growth and increased survival [1, 2]. | | Biochem/physiol Actions | Perifosine (octadecyl-(1,1-dimethyl-4-piperidylio)) is an antitumor compound. It acts at lipid rafts and stops lysosomal accumulation and mTORC1 (mammalian target of rapamycin complex 1) signaling. This drug exhibits significant antiproliferative activity in vitro and in vivo in various human cancer model systems. | | target | AKT | | storage | Store at -20°C | | Background | Perifosine, also known as KRX-0401, is a novel synthetic alkylphospholipid with a structure that closely resembles naturally occurring phospholipids. Perifosine inhibits Akt at both Ser473 and Thr308 sites via blocking pleckstrin homology domain mediated Akt cell membrane recruitment and activation. It does not directly affect PI3 Kinase or PDK1 activity. Investigators have shown that perifosine inhibits Akt in a dose dependent manner at concentrations causing cell growth inhibition in numerous cancer cell types including PC-3, multiple myeloma, and malignant pleural mesothelioma cells. Research studies have demonstrated that perifosine blocks cell cycle progression in squamous carcinoma cells by inducing p21WAF1 expression through a p53-independent pathway. Perifosine has been shown to possess a synergistic cytotoxicity with many other antineoplastic reagents. For example, investigators have demonstrated that perifosine and etoposide treatment of human leukemia T cells results in more pronounced reduction of Akt and FoxO1 phosphorylation levels, increased mitochondrial injury and caspase activation, and a marked increase in cell death. | | references | [1] elrod h a, lin y d, yue p, et al. the alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of akt and activation of the extrinsic apoptotic pathway. molecular cancer therapeutics, 2007, 6(7): 2029-2038.
[2] hideshima t, catley l, yasui h, et al. perifosine, an oral bioactive novel alkylphospholipid, inhibits akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. blood, 2006, 107(10): 4053-4062. |
| | Perifosine (KRX-0401) Preparation Products And Raw materials |
|